Publish in OALib Journal
ISSN: 2333-9721
APC: Only $99

Paper Submission

Views	Downloads

Relative Articles
Incidence and Epidemiology of Hospitalized Influenza Cases in Rural Thailand during the Influenza A (H1N1)pdm09 Pandemic, 2009–2010
Serological Response of Patients with Influenza A (H1N1) pdm09-Associated Pneumonia: An Observational Study
Socioeconomic Factors Influencing Hospitalized Patients with Pneumonia Due to Influenza A(H1N1)pdm09 in Mexico
Systemic Corticosteroids and Early Administration of Antiviral Agents for Pneumonia with Acute Wheezing due to Influenza A(H1N1)pdm09 in Japan
Effectiveness of A(H1N1)pdm09 Influenza Vaccine in Adults Recommended for Annual Influenza Vaccination
Analysis of fatal outcomes from influenza A(H1N1)pdm09 in Mongolia
Estimating the Fitness Advantage Conferred by Permissive Neuraminidase Mutations in Recent Oseltamivir-Resistant A(H1N1)pdm09 Influenza Viruses
Dynamic Patterns of Circulating Seasonal and Pandemic A(H1N1)pdm09 Influenza Viruses From 2007–2010 in and around Delhi, India
Use of Intravenous Peramivir for Treatment of Severe Influenza A(H1N1)pdm09
Mortality, Severe Acute Respiratory Infection, and Influenza-Like Illness Associated with Influenza A(H1N1)pdm09 in Argentina, 2009
More...

PLOS ONE 2013

Influenza A(H1N1)pdm09-Associated Pneumonia Deaths in Thailand

DOI: 10.1371/journal.pone.0054946

Charatdao Bunthi, Somsak Thamthitiwat, Henry C. Baggett, Pasakorn Akarasewi, Ruchira Ruangchira-urai, Susan A. Maloney, Kumnuan Ungchusak

Full-Text Cite this paper Add to My Lib

Abstract:

Background The first human infections with influenza A(H1N1)pdm09 virus were confirmed in April 2009. We describe the clinical and epidemiological characteristics of influenza A(H1N1)pdm09-associated pneumonia deaths in Thailand from May 2009-January 2010. Methods We identified influenza A(H1N1)pdm09-associated pneumonia deaths from a national influenza surveillance system and performed detailed reviews of a subset. Results Of 198 deaths reported, 49% were male and the median age was 37 years; 146 (73%) were 20–60 years. Among 90 deaths with records available for review, 46% had no identified risk factors for severe influenza. Eighty-eight patients (98%) received antiviral treatment, but only 16 (18%) initiated therapy within 48 hours of symptom onset. Conclusions Most influenza A(H1N1)pdm09 pneumonia fatalities in Thailand occurred in adults aged 20–60 years. Nearly half lacked high-risk conditions. Antiviral treatment recommendations may be especially important early in a pandemic before vaccine is available. Treatment should be considered as soon as influenza is suspected.

References

[1]	Swine influenza A (H1N1) infection in two children–Southern California, March-April 2009. MMWR Morb Mortal Wkly Rep 58: 400–402.
[2]	Update: swine influenza A (H1N1) infections–California and Texas, April 2009. MMWR Morb Mortal Wkly Rep 58: 435–437.
[3]	Outbreak of swine-origin influenza A (H1N1) virus infection - Mexico, March-April 2009. MMWR Morb Mortal Wkly Rep 58: 467–470.
[4]	Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605–2615.
[5]	Jain S, Kamimoto L, Bramley AM, Schmitz AM, Benoit SR, et al. (2009) Hospitalized patients with 2009 H1N1 influenza in the United States, April-June 2009. N Engl J Med 361: 1935–1944.
[6]	Santa-Olalla Peralta P, Cortes-Garcia M, Vicente-Herrero M, Castrillo-Villamandos C, Arias-Bohigas P, et al.. (2010) Risk factors for disease severity among hospitalised patients with 2009 pandemic influenza A (H1N1) in Spain, April - December 2009. Euro Surveill 15.
[7]	Pebody RG, McLean E, Zhao H, Cleary P, Bracebridge S, et al.. (2010) Pandemic Influenza A (H1N1) 2009 and mortality in the United Kingdom: risk factors for death, April 2009 to March 2010. Euro Surveill 15.
[8]	Dominguez-Cherit G, Lapinsky SE, Macias AE, Pinto R, Espinosa-Perez L, et al. (2009) Critically Ill patients with 2009 influenza A(H1N1) in Mexico. JAMA 302: 1880–1887.
[9]	Hospitalized patients with novel influenza A (H1N1) virus infection - California, April-May, 2009. MMWR Morb Mortal Wkly Rep 58: 536–541.
[10]	Bassetti M, Parisini A, Calzi A, Pallavicini FM, Cassola G, et al.. (2010) Risk factors for severe complications of the novel influenza A (H1N1): analysis of patients hospitalized in Italy. Clin Microbiol Infect.
[11]	Champunot R, Tanjatham S, Kerdsin A, Puangpatra P, Wangsai S, et al. (2010) Impact of pandemic influenza (H1N1) virus-associated community-acquired pneumonia among adults in a tertiary hospital in Thailand. Jpn J Infect Dis 63: 251–256.
[12]	de Silva UC, Warachit J, Waicharoen S, Chittaganpitch M (2009) A preliminary analysis of the epidemiology of influenza A(H1N1)v virus infection in Thailand from early outbreak data, June-July 2009. Euro Surveill 14.
[13]	Dulyachai W, Makkoch J, Rianthavorn P, Changpinyo M, Prayangprecha S, et al. (2010) Perinatal pandemic (H1N1) 2009 infection, Thailand. Emerg Infect Dis 16: 343–344.
[14]	Hanshaoworakul W, Simmerman JM, Narueponjirakul U, Sanasuttipun W, Shinde V, et al. (2009) Severe human influenza infections in Thailand: oseltamivir treatment and risk factors for fatal outcome. PLoS One 4: e6051.
[15]	WHO (2009) Clinical management of human infection with pandemic (H1N1) 2009, revised guidance. Available: http://www.who.int/csr/resources/publica？tions/swineflu/clinical_management_h1n1.？pdf. Accessed 2011 Jan 10.
[16]	Vaillant L, La Ruche G, Tarantola A, Barboza P (2009) Epidemiology of fatal cases associated with pandemic H1N1 influenza 2009. Euro Surveill 14.
[17]	Reichert T, Chowell G, Nishiura H, Christensen RA, McCullers JA (2010) Does Glycosylation as a modifier of Original Antigenic Sin explain the case age distribution and unusual toxicity in pandemic novel H1N1 influenza? BMC Infect Dis 10: 5.
[18]	Simmerman JM, Chittaganpitch M, Levy J, Chantra S, Maloney S, et al. (2009) Incidence, seasonality and mortality associated with influenza pneumonia in Thailand: 2005–2008. PLoS One 4: e7776.
[19]	Lee CH, Avery C, Asherin Ryan, Rainbow, et al (2011) Pandemic (H1N1) 2009-associated Deaths Detected by Unexplained Deaths and Medical Examiner Surveillance. Emerg Infect Dis 17: 1479–1483.
[20]	Louie JK, Acosta M, Winter K, Jean C, Gavali S, et al. (2009) Factors associated with death or hospitalization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 302: 1896–1902.
[21]	Yokota RT, Skalinski LM, Igansi CN, de Souza LR, Iser BP, et al. (2011) Risk factors for death from pandemic (H1N1) 2009, southern Brazil. Emerg Infect Dis 17: 1467–1471.
[22]	Tutuncu EE, Ozturk B, Gurbuz Y, Haykir A, Sencan I, et al. (2010) Clinical characteristics of 74 pandemic H1N1 influenza patients from Turkey. Risk factors for fatality. Saudi Med J 31: 993–998.
[23]	Santa-Olalla Peralta P, Cortes Garcia M, Limia Sanchez A, Andres Prado J, Pachon Del Amo I, et al. (2010) [Critically ill patients with 2009 pandemic influenza A (H1N1) infection in Spain: Factors associated with death, April 2009-January 2010.]. Rev Esp Salud Publica 84: 547–567.
[24]	Fowlkes AL, Arguin P, Biggerstaff MS, Gindler J, Blau D, et al. (2011) Epidemiology of 2009 pandemic influenza A (H1N1) deaths in the United States, April-July 2009. Clin Infect Dis 52 Suppl 1S60–68.
[25]	Cui W, Zhao H, Lu X, Wen Y, Zhou Y, et al. (2010) Factors associated with death in hospitalized pneumonia patients with 2009 H1N1 influenza in Shenyang, China. BMC Infect Dis 10: 145.
[26]	Mayoral Cortes JM, Ruiz Fernandez J, Pachon Diaz J, Navarro Mari JM, Puell Gomez L, et al. (2010) [Infection by the pandemic virus (H1N1) 2009 in Andalusia.]. Rev Esp Salud Publica 84: 517–528.
[27]	Restrepo MI, Mazo M, Anzueto A (2010) [Influenza A (H1N1). Experience in the United States]. Arch Bronconeumol 46 Suppl 213–18.
[28]	Nguyen-Van-Tam JS, Openshaw PJ, Hashim A, Gadd EM, Lim WS, et al. (2010) Risk factors for hospitalisation and poor outcome with pandemic A/H1N1 influenza: United Kingdom first wave (May-September 2009). Thorax 65: 645–651.
[29]	Muhammad Ismail HI, Tan KK, Lee YL, Pau WS, Razali KA, et al. (2011) Characteristics of children hospitalized for pandemic (H1N1) 2009, Malaysia. Emerg Infect Dis 17: 708–710.
[30]	Cox CM, Blanton L, Dhara R, Brammer L, Finelli L (2011) 2009 Pandemic influenza A (H1N1) deaths among children–United States, 2009–2010. Clin Infect Dis 52 Suppl 1S69–74.
[31]	Ungchusak K, Sawanpanyalert P, Hanchoworakul W, Sawanpanyalert N, Maloney SA, et al. (2012) Lessons learned from influenza A(H1N1)pdm09 pandemic response in Thailand. Emerg Infect Dis 18: 1058–1064.
[32]	Yokoyama T, Tsushima K, Ushiki A, Kobayashi N, Urushihata K, et al. (2010) Acute lung injury with alveolar hemorrhage due to a novel swine-origin influenza A (H1N1) virus. Intern Med 49: 427–430.
[33]	Fiore AE, Fry A, Shay D, Gubareva L, Bresee JS, et al. (2011) Antiviral agents for the treatment and chemoprophylaxis of influenza – recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 60: 1–24.
[34]	Lees CH, Avery C, Asherin R, Rainbow J, Danila R, et al. (2011) Pandemic (H1N1) 2009-associated deaths detected by unexplained death and medical examiner surveillance. Emerg Infect Dis 17: 1479–1483.
[35]	Bassetti M, Parisini A, Calzi A, Pallavicini FM, Cassola G, et al. (2011) Risk factors for severe complications of the novel influenza A (H1N1): analysis of patients hospitalized in Italy. Clin Microbiol Infect 17: 247–250.
[36]	WHO (2009) WHO recommendations on pandemic (H1N1) 2009 vaccines. Available: http://www.who.int/csr/disease/swineflu/？notes/h1n1_vaccine_20090713/en/index.htm？l. Accessed 2012 October 15.
[37]	Iamsirithaworn S, Akarasewi P, Yingyong T, Suthachana S, Pittayawonganon C, et al. (2011) Three Waves of the 2009 H1N1 Influenza Pandemic in Thailand. Siriraj Med J 63: 64–67.
[38]	Garcia-Garcia L, Valdespino-Gomez JL, Lazcano-Ponce E, Jimenez-Corona A, Higuera-Iglesias A, et al. (2009) Partial protection of seasonal trivalent inactivated vaccine against novel pandemic influenza A/H1N1 2009: case-control study in Mexico City. BMJ 339: b3928.
[39]	Palache A (2011) Seasonal influenza vaccine provision in 157 countries (2004–2009) and the potential influence of national public health policies. Vaccine 29: 9459–9466.

Full-Text